This information is intended for U.S. healthcare professionals and/or
healthcare professionals involved in healthcare reimbursement.
This site is intended for U.S. residents 18 years of age or older.
Live Support
1-800-861-0048
8 AM to 8 PM ET, Mon–Fri
We’d love your feedback on your experience today.
Please take this quick survey to help us continue to provide you with information
Supporting patient access
BMS Access Support® may help support patient access by conducting benefits reviews and offering prior authorization and appeals process assistance for enrolled patients. Additionally, the information below provides product-specific billing and diagnosis codes, reimbursement and coding guides, distribution information, and additional coverage support offerings. To view available coding and coverage information, please select your patient’s prescribed medication.
Additional eligibility criteria and terms may apply. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Read more about our coverage support offerings
Benefits Reviews
- Once a patient is enrolled in BMS Access Support, we can review their insurance coverage and provide a summary of benefits within approximately 24 hours*
- A benefits review may help determine whether or not a medication is covered, if a PA is required, and estimated patient out-of-pocket costs
*BMS Access Support Data - Benefits review. Accessed August 2022.
Prior Authorization (PA) and Appeals Assistance
- Use the BMS Access Map to identify plan-specific PA requirements
- View our forms and resources page for helpful support tools, including appeals letter templates and medical necessity letters
Annual Reverification
- Reverification of benefits is available upon request to confirm a patient's benefits for the new year
- Connect with your local Access and Reimbursement Manager for more information
Medication Menu
ONUREG®
(azacitidine) tablets
Indication(s) Important Safety Information U.S. Full Prescribing Information
The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.
Reimbursement and Coding Guide
for ONUREG
Filter results by:
National Drug Codes (NDC)1
Issued by the FDA
Note: Payers require the submission of the 11-digit NDC on healthcare claim forms. Please use the 11-digit codes shown here.
| 59572-0730-07 Copy | 200-mg tablets; one blister card containing 7 tablets |
| 59572-0740-07 Copy | 300-mg tablets; one blister card containing 7 tablets |
International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)2
| C92 Copy | Myeloid leukemia† |
| C92.0 Copy | Acute myeloblastic leukemia† |
| C92.00 Copy | Acute myeloblastic leukemia, not having achieved remission |
| C92.01 Copy | Acute myeloblastic leukemia, in remission |
| C92.5 Copy | Acute myelomonocytic leukemia† |
| C92.50 Copy | Acute myelomonocytic leukemia, not having achieved remission |
| C92.51 Copy | Acute myelomonocytic leukemia, in remission |
| C92.6 Copy | Acute myeloid leukemia with 11q23-abnormality† |
| C92.60 Copy | Acute myeloid leukemia with 11q23-abnormality, not having achieved remission |
| C92.61 Copy | Acute myeloid leukemia with 11q23-abnormality, in remission |
| C92.A Copy | Acute myeloid leukemia with multilineage dysplasia† |
| C92.A0 Copy | Acute myeloid leukemia with multilineage dysplasia, not having achieved remission |
| C92.A1 Copy | Acute myeloid leukemia with multilineage dysplasia, in remission |
| C92.Z Copy | Other myeloid leukemia† |
| C92.Z0 Copy | Other myeloid leukemia, not having achieved remission |
| C92.Z1 Copy | Other myeloid leukemia, in remission |
| C92.9 Copy | Myeloid leukemia, unspecified† |
| C92.90 Copy | Myeloid leukemia, unspecified, not having achieved remission |
| C92.91 Copy | Myeloid leukemia, unspecified, in remission |
| C93 Copy | Monocytic leukemia† |
| C93.0 Copy | Acute monoblastic/monocytic leukemia† |
| C93.00 Copy | Acute monoblastic/monocytic leukemia, not having achieved remission |
| C93.01 Copy | Acute monoblastic/monocytic leukemia, in remission |
| C94 Copy | Other leukemias of specified cell type† |
| C94.0 Copy | Acute erythroid leukemia† |
| C94.00 Copy | Acute erythroid leukemia, not having achieved remission |
| C94.01 Copy | Acute erythroid leukemia, in remission |
| C94.2 Copy | Acute megakaryoblastic leukemia† |
| C94.20 Copy | Acute megakaryoblastic leukemia, not having achieved remission |
| C94.21 Copy | Acute megakaryoblastic leukemia, in remission |
*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient's medical record, the coding requirements of each health insurer, and best coding practices. Coding guidance provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.
†This is a category code and is invalid for stand-alone use. Please use the expanded code listed below.
Please see U.S. Full Prescribing Information for ONUREG.
References:
- ONUREG (azacitidine) tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
- Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/medicare/coding-billing/icd-10-codes/2023-icd-10-cm. Accessed August 2, 2023.
The following distributors are authorized to sell ONUREG and are able to service qualified accounts.
Physician Offices
| Specialty Distributor | Phone Orders | Fax Orders and Website |
|---|---|---|
| Cardinal Health Specialty Pharmaceutical Distribution | 1‑877‑453‑3972 | https://specialtyonline.cardinalhealth.com |
| CuraScript Specialty Distribution | 1‑877‑599‑7748 | https://www.curascriptsd.com |
| McKesson Specialty Health | 1‑800‑482‑6700 | https://mscs.mckesson.com |
| Morris & Dickson Specialty | 1‑800‑710‑6100 | Fax: 1‑318‑524‑3096 https://www.mdspecialtydist.com |
| Oncology Supply | 1‑800‑633‑7555 | https://www.oncologysupply.com |
Hospitals and Infusion Centers
| Specialty Distributor | Phone Orders | Fax Orders and Website |
|---|---|---|
| ASD Healthcare | 1‑800‑746‑6273 | Fax: 1‑800‑547‑9413 https://www.asdhealthcare.com |
| Cardinal Health Specialty Pharmaceutical Distribution | 1‑866‑677‑4844 | Fax: 1‑614‑553‑6301 https://orderexpress.cardinalhealth.com |
| McKesson Plasma and Biologics | 1‑877‑625‑2566 | Fax: 1‑888‑752‑7626 https://connect.mckesson.com |
| Morris & Dickson Specialty | 1‑800‑710‑6100 | Fax: 1‑318‑524‑3096 https://www.mdspecialtydist.com |
Puerto Rico Hospitals and Clinics
| Authorized Distributor | Phone Orders | Fax Orders and Website |
|---|---|---|
| Amerisource Bergen Puerto Rico |
1‑844‑222‑2273 | https://abcorder.amerisourcebergen.com |
| Cardinal Puerto Rico (Borschow) | 1‑787‑625‑4200 | https://www.cardinalhealth.pr |
| Cesar Castillo, Inc. | 1‑787‑641‑5242 (Hospitals) 1‑787‑641‑5082 (Specialty Pharmacies) |
Fax: 1‑787‑999‑1614 https://www.facilfarmaciacci.com |
Above information is accurate as of 12/23.
ONUREG is available through external specialty pharmacies. Please check with your patient's insurance plan for the appropriate specialty pharmacy.
ONUREG can also be procured by the practice directly from one of the authorized distributors in the list above. Please ensure your practice has the durable medical equipment (DME) license in place to bill the appropriate DME Medicare Administrative Contractor (DME MAC).
Please see U.S. Full Prescribing Information for ONUREG.
FDA Approval Letter as Posted by the FDA:
ONUREG for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy – Approved on 09/01/2020
View LetterPlease see U.S. Full Prescribing Information for ONUREG.
